Trial Profile
Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 01 Dec 2015 Results of post hoc analysis (n=59) published in the Anticancer Research
- 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 11 Sep 2012 Results with focus on secondary endpoints published in Annals of Oncology.